MARKET

ATRA

ATRA

Atara Biotherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.01
-0.35
-2.28%
Pre Market: 15.10 +0.09 +0.60% 08:58 06/21 EDT
OPEN
15.13
PREV CLOSE
15.36
HIGH
15.30
LOW
14.84
VOLUME
2.00K
TURNOVER
--
52 WEEK HIGH
28.20
52 WEEK LOW
10.64
MARKET CAP
1.26B
P/E (TTM)
-3.8844
1D
5D
1M
3M
1Y
5Y
Kristin Yarema Is The SVP & Chief Commercial Officer of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) And They Just Picked Up 165% More Shares
Those following along with Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) will no doubt be intrigued by the recent...
Simply Wall St. · 3d ago
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15)
Benzinga · 5d ago
Insider Trends: Insider Buying Added to with Purchase of Atara Biotherapeutics Shares
MT Newswires · 5d ago
Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant Patients
Benzinga · 06/07 16:40
Atara Biotherapeutics Highlights Presentation Of Tab-cel Long-Term Overall Survival Data For Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant: All Patients Showed Complete Or Partial Response At 1 Year
All patients with a complete response (CR) or a partial response (PR) to tab-cel® alive at one year Overall tab-cel® survival benefit demonstrated across previous treatment subgroups Phase 2 results validate
Benzinga · 06/07 14:31
Atara Biotherapeutics Presents Positive Tab-cel(R) Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
--Overall tab-cel(R) survival benefit demonstrated across previous treatment subgroups
Business Wire · 06/07 14:30
Atara Biotherapeutics Reports 'Positive' Tab-Cel Data From Three Clinical Studies, Shares Rise 5%
MT Newswires · 06/07 13:04
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregat...
Business Wire · 06/04 20:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRA. Analyze the recent business situations of Atara Biotherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRA stock price target is 35.29 with a high estimate of 78.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 212
Institutional Holdings: 91.01M
% Owned: 108.25%
Shares Outstanding: 84.08M
TypeInstitutionsShares
Increased
61
8.99M
New
23
680.08K
Decreased
42
8.36M
Sold Out
19
753.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.57%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Chairman/Director
Ronald Renaud
President/Chief Executive Officer/Director
Pascal Touchon
Chief Financial Officer/Senior Vice President
Utpal Koppikar
Chief Operating Officer/Executive Vice President
Joseph Newell
Executive Vice President
Jakob Dupont
Senior Vice President/General Counsel
K. Amar Murugan
Senior Vice President
Kristin Yarema
Senior Vice President
Kanya Rajangam
Lead Director/Independent Director
Carol Gallagher
Director
Maria Roncarolo
Independent Director
Roy Baynes
Independent Director
Eric Dobmeier
Independent Director
Matthew Fust
Independent Director
William Heiden
Independent Director
Beth Seidenberg
No Data
About ATRA
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Webull offers kinds of Atara Biotherapeutics Inc stock information, including NASDAQ:ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.